Evidence map›Paper›PMID 37614573›Full record

ArticleJACC. CardioOncology2023

Risk of Cancer After Diagnosis of Cardiovascular Disease.

Caitlin F Bell, Xiudong Lei, Allen Haas, Richard A Baylis, Hua Gao, Lingfeng Luo, Sharon H Giordano, Mackenzie R Wehner, Kevin T Nead, Nicholas J Leeper

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

94 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Observational
  19. Article
  20. Article

34 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Caitlin F BellDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.
Xiudong LeiDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Allen HaasDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Richard A BaylisDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, California, USA.
Hua GaoDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, California, USA.
Lingfeng LuoDepartment of Surgery, Division of Vascular Surgery, Stanford University School of Medicine, Stanford, California, USA.
Sharon H GiordanoDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mackenzie R WehnerDepartment of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kevin T NeadDepartment of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas J LeeperDepartment of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California, USA.

Funding

Clonal expansion, resistance to efferocytosis and innate immunity in atherosclerosisR35HL144475 · NHLBI · STANFORD UNIVERSITY · PI LEEPER, NICHOLAS JAMES · 2019 to 2024
$5.1M
NHLBI NIH HHS R35 HL144475
6 · The paper itself

Abstract

Background: Cardiovascular disease (CVD) and cancer share several risk factors. Although preclinical models show that various types of CVD can accelerate cancer progression, clinical studies have not determined the impact of atherosclerosis on cancer risk. Objectives: The objective of this study was to determine whether CVD, especially atherosclerotic CVD, is independently associated with incident cancer. Methods: Using IBM MarketScan claims data from over 130 million individuals, 27 million cancer-free subjects with a minimum of 36 months of follow-up data were identified. Individuals were stratified by presence or absence of CVD, time-varying analysis with multivariable adjustment for cardiovascular risk factors was performed, and cumulative risk of cancer was calculated. Additional analyses were performed according to CVD type (atherosclerotic vs nonatherosclerotic) and cancer subtype. Results: Among 27,195,088 individuals, those with CVD were 13% more likely to develop cancer than those without CVD (HR: 1.13; 95% CI: 1.12-1.13). Results were more pronounced for individuals with atherosclerotic CVD (aCVD), who had a higher risk of cancer than those without CVD (HR: 1.20; 95% CI: 1.19-1.21). aCVD also conferred a higher risk of cancer compared with those with nonatherosclerotic CVD (HR: 1.11; 95% CI: 1.11-1.12). Cancer subtype analyses showed specific associations of aCVD with several malignancies, including lung, bladder, liver, colon, and other hematologic cancers. Conclusions: Individuals with CVD have an increased risk of developing cancer compared with those without CVD. This association may be driven in part by the relationship of atherosclerosis with specific cancer subtypes, which persists after controlling for conventional risk factors.

Indexed as

atherosclerosiscardiovascular diseaseepidemiologymedical claimsrisk prediction

Identifiers

PMID37614573
PMCPMC10443115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.